Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Nivolumab (anti-PD-1), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to PDCD1/PD-1/CD279, >95%, high purity, Human IgG4SP, Antibody of programmed cell death 1 (CD279)

Features and benefits
  • Short Overview:

    Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Application: ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
  • Species reactivity(Reacts with): Cynomolgus monkey,Human
  • Isotype: Human IgG4SP
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
N411994
Grouped product items
SKUSizeAvailabilityPrice Qty
N411994-1mg
1mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$159.90
N411994-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$664.90
N411994-10mg
10mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$1,196.90
Add to Wish List Compare
Bulk Order  DATASHEET

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series
Click to view target information: PDCD1
Accession#:Q15116 Gene ID:5133 PD1 PDCD1 programmed cell death 1 (CD279) Antibody

Basic Description

Product NameNivolumab (anti-PD-1), for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to PDCD1/PD-1/CD279, >95%, high purity, Human IgG4SP
SynonymsCID 167682467 | hPD-1 | Protein PD-1
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
SpecificityPDCD1/PD-1/CD279
ApplicationELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeINHIBITOR
Mechanism of actionAntibody of programmed cell death 1 (CD279)
Product Description

Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg 

Product Properties

Antibody TypePrimary antibody
ClonalityRecombinant
IsotypeHuman IgG4SP
SDS-PAGE26.4 kDa (Light Chain) & 53.3 kDa (Heavy Chain), under reducing conditions; 178.6 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
SourceCHO supernatant
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS946414-94-4

Images

Nivolumab (anti-PD-1) (N411994) - Flow Cytometry
Flow Cytometry analysis of PHA-stimulated (3 days) human peripheral blood mononuclear lymphocytes labelling PD-1 (red) with Nivolumab (anti-PD-1) (N411994). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Nivolumab (anti-PD-1) (N411994) - SEC
The purity of Nivolumab (anti-PD-1) (N411994) is more than 95% verified by HPLC.

Associated Targets(Human)

PDCD1 Tclin Programmed cell death protein 1 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PDCD1 Tclin Programmed cell death protein 1 (14 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDCD1 Tclin Programmed cell death protein 1/Programmed cell death 1 ligand 1 (1367 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot NumberCertificate TypeDateItem
ZJ23F0800920Certificate of AnalysisAug 26, 2023 N411994
ZJ23F0800919Certificate of AnalysisAug 26, 2023 N411994
ZJ23F0800918Certificate of AnalysisAug 26, 2023 N411994

Related Documents

 SDS

 Specification Sheet

FAQs and Articles

FAQ
Flow cytometry protocol
Categories: Protocols
Tags:
Antibodies Flow Cytometry Flow Antibodies Reactive dyes Indirect antibody labelling

References

1. Janakiram M, Abadi YM, Sparano JA, Zang X.  (2012)  T cell coinhibition and immunotherapy in human breast cancer..  Discov Med,  14  (77): (229-36).  [PMID:23114578]
2. Greaves P, Gribben JG.  (2013)  The role of B7 family molecules in hematologic malignancy..  Blood,  121  (5): (734-44).  [PMID:23223433]
3. Tang PA, Heng DY.  (2013)  Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer..  Curr Oncol Rep,  15  (2): (98-104).  [PMID:23263823]
4. Hamid O, Carvajal RD.  (2013)  Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy..  Expert Opin Biol Ther,  13  (6): (847-61).  [PMID:23421934]
5. Intlekofer AM, Thompson CB.  (2013)  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy..  J Leukoc Biol,  94  (1): (25-39).  [PMID:23625198]
6. Callahan MK, Wolchok JD.  (2013)  At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy..  J Leukoc Biol,  94  (1): (41-53).  [PMID:23667165]
7. O'Sullivan Coyne G, Madan RA, Gulley JL.  (2014)  Nivolumab: promising survival signal coupled with limited toxicity raises expectations..  J Clin Oncol,  32  (10): (986-8).  [PMID:24590655]
8. Luke JJ, Ott PA.  (2015)  PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma..  Oncotarget,  6  (6): (3479-92).  [PMID:25682878]
9. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al..  (2015)  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma..  N Engl J Med,  372  (21): (2006-17).  [PMID:25891304]
10. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al..  (2015)  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma..  N Engl J Med,  373  (1): (23-34).  [PMID:26027431]
11. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al..  (2015)  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma..  N Engl J Med,  373  (19): (1803-13).  [PMID:26406148]
12. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al..  (2018)  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma..  N Engl J Med,  378  (14): (1277-1290).  [PMID:29562145]
13. Pardoll DM.  (2012)  The blockade of immune checkpoints in cancer immunotherapy..  Nat Rev Cancer,  12  (4): (252-64).  [PMID:22437870]
14. Topalian SL, Drake CG, Pardoll DM.  (2015)  Immune checkpoint blockade: a common denominator approach to cancer therapy..  Cancer Cell,  27  (4): (450-61).  [PMID:25858804]
15. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al..  (2004)  The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)..  Genome Res,  14  (10B): (2121-7).  [PMID:15489334]
16. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K et al..  (2004)  Complete sequencing and characterization of 21,243 full-length human cDNAs..  Nat Genet,  36  (1): (40-5).  [PMID:14702039]
17. Kline J, Gajewski TF.  (2010)  Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer..  Curr Opin Investig Drugs,  11  (12): (1354-9).  [PMID:21154117]
18. Hall RD, Gray JE, Chiappori AA.  (2013)  Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer..  Cancer Control,  20  (1): (22-31).  [PMID:23302904]
19. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al..  (2017)  Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice..  Mol Cancer Ther,  16  (5): (861-870).  [PMID:28265006]
20. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA.  (2015)  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1..  Structure,  23  (12): (2341-2348).  [PMID:26602187]
21. L R Finger,J Pu,R Wasserman,R Vibhakar,E Louie,R R Hardy,P D Burrows,L G Billips.  (1997-10-23)  The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors..  Gene,  197  ((1-2)): (177-187).  [PMID:9332365]
22. Cheng B, Ren Y, Niu X, Wang W, Wang S, Tu Y, Liu S, Wang J, Yang D, Liao G, Chen J..  (2020)  Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents..  J Med Chem,  63  (15): (8338-8358).  [PMID:32667799]
23. Shinohara, T T, Taniwaki, M M, Ishida, Y Y, Kawaichi, M M and Honjo, T T..  (1994)  Structure and chromosomal localization of the human PD-1 gene (PDCD1)..  Genomics,      [PMID:7851902]
24. Prokunina, Ludmila L and 23 more authors..  (2002)  A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans..  Nature genetics,      [PMID:12402038]
25. Fife, Brian T BT and Pauken, Kristen E KE..  (2011)  The role of the PD-1 pathway in autoimmunity and peripheral tolerance..  Annals of the New York Academy of Sciences,      [PMID:21276005]
26. Topalian, Suzanne L SL and 29 more authors..  (2012)  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer..  The New England journal of medicine,    (28):   [PMID:22658127]
27. Cheng, Xiaoxiao X and 18 more authors..  (2013)  Structure and interactions of the human programmed cell death 1 receptor..  The Journal of biological chemistry,    (26):   [PMID:23417675]
28. Robert, Caroline C and 27 more authors..  (2015)  Nivolumab in previously untreated melanoma without BRAF mutation..  The New England journal of medicine,    (22):   [PMID:25399552]
29. McDermott, J J and Jimeno, A A..  (2015)  Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer..  Drugs of today (Barcelona, Spain : 1998),      [PMID:25685857]
30. Na, Zhenkun and 6 more authors..  (2017)  Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab..  Cell research,      [PMID:27325296]
31. Pascolutti, Roberta R and 6 more authors..  (2016)  Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant..  Structure (London, England : 1993),    (4):   [PMID:27618663]
32. Horita, Shoichiro S and 5 more authors..  (2016)  High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1..  Scientific reports,    (13):   [PMID:27734966]
33. Tan, Shuguang S and 15 more authors..  (2017)  An unexpected N-terminal loop in PD-1 dominates binding by nivolumab..  Nature communications,    (6):   [PMID:28165004]
34. Berger, Kristin Nicole KN and Pu, Jeffrey Jiayu JJ..  (2018)  PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene..  Gene,    (5):   [PMID:28951311]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.